ライフサイエンスコーパス: macrophage activation syndrome

1 ndrome (of whom 2 eventually developed overt macrophage activation syndrome).

2 usion reactions, dose-limiting toxicities or macrophage activation syndrome.

3 d (5) hemophagocytic lymphohistiocytosis and macrophage activation syndrome.

4 ted intravascular coagulation as features of macrophage activation syndrome.

5 e into a life-threatening condition known as macrophage activation syndrome.

6 sCD163 are promising diagnostic markers for macrophage activation syndrome.

7 comparable with those in patients with acute macrophage activation syndrome.

8 also help identify patients with subclinical macrophage activation syndrome.

9 requently associated with the development of macrophage activation syndrome.

10 nd the relationship between systemic JIA and macrophage activation syndrome.

11 e a unique subset in MIS-C versus FC without macrophage activation syndrome.

12 ohistiocytosis syndrome (HLS), also known as macrophage activation syndrome.

13 derpins the pathology of Still's disease and macrophage activation syndrome.

14 emophagocytic lymphohistiocytosis, including macrophage activation syndrome.

15 -10, IL-1a, and SDF-1 and incipient signs of macrophage activation syndrome.

16 Il-18bp knockout (KO) mice with CpG-induced macrophage activation syndrome.

17 ence of cardiohemodynamic involvement and no macrophage activation syndrome.

18 identify key aspects of the pathogenesis of macrophage activation syndrome.

19 e to haemophagocytic lymphohistiocytosis and macrophage activation syndrome.

20 odel mimics pathophysiologic features of HLS/macrophage activation syndrome.

21 ects the pathogenesis of Still's disease and macrophage activation syndrome.

22 ction, or hemophagocytic lymphohistiocytosis-macrophage-activation syndrome.

23 ses, disturbances in cytokine signaling, and macrophage activation syndromes.

24 rheumatoid arthritis is the association with macrophage activation syndrome, a life-threatening compl

25 tients with Still's disease may also develop macrophage activation syndrome, a potentially fatal comp

26 is trials, anakinra is effective in treating macrophage activation syndrome, a similar entity with fe

27 changes are consistent with the presence of macrophage activation syndrome and could furthermore be

28 such dysregulation and the relation between macrophage activation syndrome and hemophagocytic lympho

29 in response to Ifn-gamma during CpG-induced macrophage activation syndrome and is present at high le

30 urrent understanding of the relation between macrophage activation syndrome and other clinically simi

31 emophagocytic lymphohistiocytosis, including macrophage activation syndrome, and cytokine release syn

32 positivity, immune dysregulation biomarkers, macrophage activation syndrome, and death.

33 he interferon-gamma-driven cytokine storm in macrophage activation syndrome, and is more pronounced i

34 neonatal disease includes some hallmarks of macrophage activation syndrome but is much more severe t

35 63 levels in sera from 7 patients with acute macrophage activation syndrome complicating systemic JIA

36 m sIL-2Ralpha and sCD163 in diagnosing acute macrophage activation syndrome complicating systemic juv

37 emophagocytic histiocytes from patients with macrophage activation syndrome display prominent mTORC1

38 Hence, sepsis patients with macrophage activation syndrome features may benefit from

39 ospective randomized trial using features of macrophage activation syndrome for mortality risk strati

40 tin levels (including those with subclinical macrophage activation syndrome) from those with normal o

41 One death was related to liso-cel (macrophage activation syndrome-haemophagocytic lymphohis

42 Clinically, macrophage activation syndrome has strong similarities w

43 cytosis) without previous therapy, including macrophage activation syndrome (hemophagocytic lymphohis

44 with a cytokine signature similar to that of macrophage activation syndrome/hemophagocytic lymphohist

45 ut so are cytokines that are associated with macrophage activation syndrome/hemophagocytic lymphohist

46 on to the successful use of cyclosporine for macrophage activation syndrome in JRA.

47 g can be a useful tool for identifying early macrophage activation syndrome in patients with systemic

48 assification, pathogenesis and management of macrophage activation syndrome in systemic onset juvenil

49 to further elucidate the pathophysiology of macrophage activation syndrome in systemic onset juvenil

50 s of perforin expression may be a feature of macrophage activation syndrome in systemic-onset juvenil

51 ght contribute to the increased incidence of macrophage activation syndrome in these patients.

52 ammatory disorders and is usually designated macrophage activation syndrome in those settings.

53 elated with clinical features of established macrophage activation syndrome, including ferritin level

54 n be damaging to the host, as is seen in the macrophage activation syndrome induced by severe infecti

55 Macrophage activation syndrome is a life-threatening com

56 Macrophage activation syndrome is characterized by an ov

57 Macrophage activation syndrome is the rheumatic disease-

58 through the mediators hyperferritinemia and macrophage activation syndrome (MAS) and also had direct

59 h diverse clinical manifestations, including macrophage activation syndrome (MAS) and lung disease (L

60 ntrations associate with disease activity in macrophage activation syndrome (MAS) and poor clinical o

61 etween MIS-C, and the inflammatory syndromes macrophage activation syndrome (MAS) and thrombotic micr

62 Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are 2 similar disea

63 hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are both characteri

64 Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatenin

65 The deadly macrophage activation syndrome (MAS) constitutes one of

66 features of HLH, using modified HLH-2004 and macrophage activation syndrome (MAS) criteria.

67 Macrophage activation syndrome (MAS) is a devastating cy

68 Macrophage activation syndrome (MAS) is an acute episode

69 Indeed, the severity of CpG-induced macrophage activation syndrome (MAS) is exacerbated in I

70 The pathogenesis of macrophage activation syndrome (MAS) is not clearly unde

71 hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) occur after chimeri

72 Macrophage activation syndrome (MAS), a major cause of m

73 it life-threatening complications, including macrophage activation syndrome (MAS), a secondary form o

74 -18/IL-18BP balance could be dysregulated in macrophage activation syndrome (MAS), as mirrored by the

75 erinflammatory 'cytokine storm' state termed macrophage activation syndrome (MAS), culminating from a

76 ia in TLR7-overexpressing mice, which have a macrophage activation syndrome (MAS)-like disease.

77 mic juvenile idiopathic arthritis (SJIA) and macrophage activation syndrome (MAS).

78 hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).

79 mphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).

80 auses early-onset recurrent fever flares and macrophage activation syndrome (MAS).

81 ous forms of secondary HLH (sHLH), including macrophage activation syndrome (MAS).

82 istoric cohorts of Kawasaki disease (KD) and macrophage activation syndrome (MAS).RESULTSTwenty-eight

83 both hemophagocytic lymphohistiocytosis and macrophage activation syndrome, natural killer and cytot

84 The macrophage activation syndrome occurred in 7 patients; i

85 IA, 5 of whom showed evidence of subclinical macrophage activation syndrome (of whom 2 eventually dev

86 ilial HLH) and excess interleukin-18 (IL-18; macrophage activation syndrome) provide clues.

87 Two of these 5 patients developed overt macrophage activation syndrome several months later.

88 including hemophagocytic lymphohistiocytosis/macrophage activation syndrome, severe malarial anemia d

89 Fifty-eight patients (17%) developed macrophage-activation syndrome, sometimes related to acu

90 d severe, persistent, or relapsing secondary macrophage activation syndrome, the addition of prompt i

91 an level of sIL-2Ralpha in the patients with macrophage activation syndrome was 19,646 pg/ml (interqu

92 the median level of sCD163 in patients with macrophage activation syndrome was 23,000 ng/ml (IQR 14,

93 ne effector cell-associated neurotoxicity or macrophage activation syndromes were reported.

94 ell findings may suggest a relationship with macrophage activation syndrome, while type 1 DC upregula

95 In patients with macrophage activation syndrome, whose disease does not s

96 e, including both inflammatory arthritis and macrophage activation syndrome with hemophagocytosis, a